Monday, May 23, 2022

Lower risk of vaccine-success infection for mRNA-1273 recipients

Recently, a team of researchers examined breakthrough infections, hospitalizations, and mortality in double-dose messenger RNA (mRNA) vaccine recipients, in a paper published in the journal Medicines. Journal of the American Medical Association (JAMA),

Vaccine-induced immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) six months after administration of mRNA vaccines – BNT162b2 (Pfizer) and mRNA-1273 (Moderna). There have been several reports of vaccine-success infections, which is another cause for concern.

The latest surge in cases of the coronavirus disease 2019 (COVID-19) in several countries has been alarming, due to the new, highly mutated SARS-CoV-2 Omicron variant. As a result, many countries have approved the administration of booster doses of COVID-19 vaccines to control the number of infections.

Research paper: Comparison of mRNA-1273 and BNT162b2 vaccines on breakthroughs in SARS-CoV-2 infection, hospitalization and death during the delta-dominant period. Image credit: Karl DeMaster / Shutterstock

the study

The current study collected electronic health records (EHRs) of COVID-19 patients showing diverse geography, race, ethnicity and income.

Cloud-based platform TriNetX Analytics was used to access and analyze patient-level data. Successful infection of individuals who received two doses of BNT162b2 and mRNA-1273 vaccines between December 2020 and November 2021 and tested positive for SARS-CoV-2 RNA 14 days after the second vaccination between July 2021 and November 2021 was included in the study.

Read Also:  Omicron more contagious to young children, less severe than Delta

In addition, these individuals had no prior history of SARS-CoV-2 infection and did not receive a booster shot of the SARS-CoV-2 vaccine.

Matched propensity scores for the two groups – the mRNA-1273 and BNT162b2 groups – were used for analysis of demographics, social determinants of health, transplantation, COVID-19-related comorbidities, and Kaplan–Meier survival and Cox proportional hazards analysis. Cases of conclusive infection per 1,000 person-days (monthly incidence rate) were compared between the two groups.

test result

A total of approximately 62,628 and 574,538 fully vaccinated individuals received mRNA-1273 and BNT162b2 vaccines, which included approximately 3078 and 18,737 successful infections, respectively. The authors noted that the mRNA-1273 cohort included older people and had more COVID-19-related comorbidities relative to the BNT162b2 cohort. However, propensity score matching reduced these differences. An increase in the monthly incidence rate of success infection was observed in both groups from July 2021 to November 2021, but it was comparatively higher for the BNT162b2 cohort than for the mRNA-1273 cohort.

Hospitalization and mortality in patients infected 60 days after a positive test were analyzed and compared between the two cohorts. The risk of hospitalization was found to be 12.7% for mRNA-1273 vaccines and 13.3% for BNT162b2 vaccine recipients. The mortality rates for mRNA-1273 and BNT162b2 recipients were 1.14% and 1.1%, respectively. After propensity-score matching of the two groups, the authors observed a lower risk of hospitalization for those who received two doses of Moderna vaccine compared with those who were fully vaccinated with the BNT162B2 vaccine. Was. Mortality did not show any significant difference between the two groups after matching.

Read Also:  If blood pressure rises upon standing, so may risk for heart attack


The present study, which was conducted when the SARS-CoV-2 delta variant was the predominant strain, noted that successive infections were lower in people receiving mRNA-1273 vaccine than in BNT162b2 vaccine recipients. Similarly, the risk of hospitalization was observed to be lower for infected individuals receiving Moderna Vaccine. The hazard ratios were also significantly lower for the matched mRNA-1273 cohort than for the matched BNT162b2 cohort.

Although the study observed significant differences between the two groups, this is limited by some factors including the observational and retrospective nature of the study, which may introduce selection and follow-up biases.

Journal Reference:

  • Wang, Lindsay, Pamela B. Davis, David C. Kelber, Nora D. Volkow, and Rong Xu. “Comparison of mRNA-1273 and BNT162B2 vaccines against breakthrough SARS-CoV-2 infection, hospitalization, and death during the delta-major period.” jama, January 20, 2022, DOI:,


Nation World News Desk
Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -